Comparison of the effects of two different doses of Filgrastim in febrile neutropenia management in childhood malignancy: A randomized clinical trial

نویسندگان
Mirbehbahani, Nargesbeigom ID 1
Bagheri, Sepide ID 2
Rashidbaghan, Azam ID 3
Roshandel, Gholamreza ID 4
Jahazi , Azam ID 5

1 1Professor, MD, Neonatal and Children’s Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran

2 MD, Golestan University of Medical Sciences, Gorgan, Iran

3 4Ph.D candidate, Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

4 Ph.D, Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.

5 Gorgan Branch, Islamic Azad University, Gorgan, Iran

doi
10.18502/ijpho.v12i3.10057
چکیده

Background: Febrile neutropenia (FN) is most often caused due to chemotherapy. Solid or certain lymphoproliferative malignancies can increase the duration of hospitalization and other complications in cancer patients. Filgrastim is used in childhood FN management. This study aimed to compare the effect of two different doses of Filgrastim on hematological ...

کلیدواژه‌ها
Cancer, Filgrastim, Febrile neutropenia, Hematological factors